#1 Clinical Trials Search in Europe

Thalidomide

Thalidomide, once infamous for its teratogenic effects, is now being investigated for its therapeutic potential in various medical conditions. This article explores recent clinical trials using thalidomide to treat a range of disorders, including beta-thalassemia, chronic radiation proctitis, syringomyelia, and hereditary hemorrhagic telangiectasia. These studies aim to evaluate the drug’s efficacy, safety, and potential benefits in managing these challenging conditions.

Table of Contents

What is Thalidomide?

Thalidomide is a medication that has been used to treat various conditions, particularly in the field of oncology (cancer treatment) and dermatology (skin conditions). It was originally developed in the 1950s as a sedative but was later found to have serious side effects when used during pregnancy. However, researchers discovered that thalidomide has beneficial effects in treating certain diseases, leading to its controlled reintroduction in medical practice[1].

Conditions Treated with Thalidomide

Thalidomide is used to treat several conditions, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow. Thalidomide is often used in combination with other drugs to treat newly diagnosed and relapsed/refractory multiple myeloma[2][6].
  • Skin Sarcoidosis: A condition that causes inflammation in various organs, including the skin. Thalidomide has shown potential benefits in treating skin lesions associated with sarcoidosis[1].
  • HIV-associated Kaposi’s Sarcoma: A type of cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, or in other organs. Thalidomide has been studied for its potential in treating this condition in HIV patients[5].
  • Advanced Colorectal Cancer: Thalidomide has been investigated in combination with other drugs for treating advanced colorectal cancer after standard chemotherapy[3].

How Thalidomide Works

Thalidomide works through several mechanisms:

  • Anti-angiogenic effects: It can stop the growth of new blood vessels to tumors, potentially slowing or stopping cancer growth[5].
  • Immunomodulatory effects: Thalidomide can modify the body’s immune response, which may be beneficial in treating certain conditions[1].
  • Anti-inflammatory properties: It can help reduce inflammation in various conditions, such as skin sarcoidosis[1].

How Thalidomide is Administered

Thalidomide is typically administered orally (by mouth) in the form of capsules or tablets. The dosage and duration of treatment can vary depending on the condition being treated and the individual patient’s response. For example:

  • In multiple myeloma treatment, doses may range from 50 mg to 400 mg daily, often given in combination with other medications[2][6].
  • For skin sarcoidosis, a study used 150 mg daily for 3 months[1].
  • In advanced colorectal cancer, a dose of 150 mg daily was used in combination with other drugs[3].

Thalidomide in Combination Therapies

Thalidomide is often used in combination with other medications to enhance its effectiveness. Some common combinations include:

  • Thalidomide + Dexamethasone: This combination is used in multiple myeloma treatment[2].
  • Thalidomide + Melphalan + Prednisone: Known as the MPT regimen, this combination is used in elderly patients with newly diagnosed multiple myeloma[6].
  • Thalidomide + Tegafur/Uracil (UFUR): This combination has been studied in advanced colorectal cancer[3].
  • Thalidomide + Bortezomib + Dexamethasone: This combination, sometimes with the addition of cyclophosphamide, has been studied in multiple myeloma treatment[8].

Potential Side Effects and Safety Concerns

Thalidomide can cause several side effects and has significant safety concerns:

  • Birth defects: Thalidomide is known to cause severe birth defects if taken during pregnancy. Strict precautions are necessary for patients of childbearing potential[7].
  • Peripheral neuropathy: This is a type of nerve damage that can cause numbness, tingling, or pain in the hands and feet[2].
  • Blood clots: Thalidomide can increase the risk of blood clots, especially when used in combination with other drugs[10].
  • Drowsiness and dizziness: As thalidomide was originally developed as a sedative, it can cause these effects[1].
  • Other side effects: These may include constipation, skin rash, and a decrease in white blood cell count[2].

Due to these risks, thalidomide is typically prescribed under strict safety programs and monitoring.

Ongoing Research and Future Prospects

Research on thalidomide continues, with ongoing clinical trials exploring its use in various conditions and in combination with other drugs. Some areas of current research include:

  • Optimizing dosages and combinations for multiple myeloma treatment[8][9].
  • Investigating its potential in other types of cancer and inflammatory conditions[3][1].
  • Exploring its use in combination with newer drugs to improve efficacy and reduce side effects[10].

As research progresses, our understanding of thalidomide’s benefits and risks continues to evolve, potentially leading to improved treatments for patients with various conditions.

Condition Study Design Dosage Primary Outcome Measures Duration
Beta-thalassemia Non-randomized, open-label 1.5 mg/kg/day (range 1-2 mg/kg/day) Change in hemoglobin levels, transfusion dependency 12 months
Chronic radiation proctitis Prospective, open-label 50-100 mg/day Remission rate of rectal bleeding 4 months treatment, 6 months follow-up
Syringomyelia Phase II clinical trial 50-200 mg/day Change in ASIA score 3 months
Hereditary hemorrhagic telangiectasia Single-arm study 50-200 mg/day Reduction in epistaxis frequency and severity Up to 24 weeks

FAQ

  • What conditions are being studied with thalidomide in clinical trials? Clinical trials are investigating thalidomide for various conditions, including beta-thalassemia, chronic radiation proctitis, syringomyelia, hereditary hemorrhagic telangiectasia, and refractory epilepsy.
  • How is thalidomide being used in beta-thalassemia trials? In beta-thalassemia trials, thalidomide is being studied to potentially reduce transfusion dependency, improve hemoglobin levels, and enhance the quality of life for patients with this genetic blood disorder.
  • What are the potential benefits of thalidomide in chronic radiation proctitis? Thalidomide is being investigated for its ability to reduce intractable bleeding in chronic radiation proctitis, potentially improving symptoms and quality of life for patients who have undergone pelvic radiotherapy.
  • Are there any safety concerns with using thalidomide in these trials? Yes, safety is a major concern in thalidomide trials. Researchers closely monitor patients for side effects, and strict protocols are in place to prevent pregnancy due to thalidomide's known teratogenic effects.
  • How long do these clinical trials typically last? The duration of thalidomide clinical trials varies depending on the condition being studied. Some trials last for several months, while others may continue for up to two years to assess long-term effects and safety.

Ongoing Clinical Trials on Thalidomide

  • Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark France Norway Spain +1

  • Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia Greece Italy

Glossary

  • Thalidomide: A drug originally used as a sedative, now being studied for its potential therapeutic effects in various conditions due to its anti-inflammatory, immunomodulatory, and anti-angiogenic properties.
  • Beta-thalassemia: A genetic blood disorder characterized by reduced or absent production of beta-globin chains, leading to anemia and other complications.
  • Chronic radiation proctitis: An inflammatory condition of the rectum that can occur as a side effect of radiation therapy for pelvic cancers.
  • Syringomyelia: A disorder where a fluid-filled cyst (syrinx) forms within the spinal cord, potentially causing pain, weakness, and other neurological symptoms.
  • Hereditary hemorrhagic telangiectasia: A genetic disorder that causes abnormal blood vessel formation, leading to bleeding and other complications.
  • Transfusion dependency: A condition where a patient requires regular blood transfusions to maintain adequate hemoglobin levels.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body.
  • Teratogenic: Capable of causing birth defects or abnormalities in a developing fetus.
  • Anti-angiogenic: A property that inhibits the growth of new blood vessels.
  • Immunomodulatory: Capable of modifying or regulating immune system functions.

References

  1. https://clinicaltrials.gov/study/NCT00305552
  2. https://clinicaltrials.gov/study/NCT00006890
  3. https://clinicaltrials.gov/study/NCT00890188
  4. https://clinicaltrials.gov/study/NCT00358020
  5. https://clinicaltrials.gov/study/NCT00019123
  6. https://clinicaltrials.gov/study/NCT00367185
  7. https://clinicaltrials.gov/study/NCT00787436
  8. https://clinicaltrials.gov/study/NCT02586038
  9. https://clinicaltrials.gov/study/NCT01971658
  10. https://clinicaltrials.gov/study/NCT00406978